, accelerators originally designed for scien tific research have found a large number of industrial and medical applications.
Low energy accelerators for research (including biomedicine) -1000
Synchrotron radiation sources >100
Medical radioisotope production -200
Radiotherapy accelerators >7500
Accelerators for industrial processing and research -1500
Ion implanters, modification of surfaces and matter in bulk >7000 TOTAL >17500 Table 1 : World accelerators running in 2003 [1] .
In the most advanced treatments the X-ray dose is given from many (5-10) ports by rotating the electron linac around the patient and modulating the shape and intensity of each port sep arately using computer-controlled multileaf-collimators. With this Intensity M odulated Radio Therapy (IMRT) the most conformal X-ray treatment can be given at the expense of a greater integral dose, which is nevertheless distributed to the normal tissues around the target.
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Article available at http://www.europhvsicsnews.org or http://dx.doi As the induction of secondary tumours is rather a volume than a dose effect, a better cure with lower risk becomes possible when the physical properties of the radiation are changed. This is possi ble by the transition from X-rays to ion beams such as protons or carbon.
The depth-dose curves of proton and light ion beams are completely different from those of X-rays because these charged particles have little scattering in matter and give the highest dose near the end of their range in the 'Bragg peak' ( For mono-energetic ions the Bragg peak, shown in Fig. 1 , is very narrow, so that the energy of the particles has to be changed dur ing the irradiation to cover the tumour depth. In cyclotrons the beam energy cannot be varied, so that movable energy absorbers and magnetic selection systems have to be used to adapt the range of the particles to the depth of the target to be irradiated. In syn chrotrons it is easy to vary the energy of the extracted beam.
Until 1997 relatively simple 'passive spreading systems' have been used to produce a Spread Out Bragg Peak (SOBP) in all hadrontherapy centres. In this approach, a first 'scatterer' widens the pencil beam while their energy is adapted to the dis tal form of the tumour by using appropriate absorbers. In this 'active spreading' technique the target volume is divided into slices of equal particle energy and each slice is divided into small volumes called 'spot' or 'voxels' (i.e. 3D pixels) that are treat ed separately by moving transversally the beam by means of bending magnets. When one slice has been treated, the energy of the beam is reduced for the next slice. In practice, the complete target volume consists of 10,000 -30,000 voxels which are treated in 2-6 minutes. All recent hadrontherapy facilities have the possi bility of using active systems. Most existing facilities still use protons delivered in fixed horizontal beam fines, combined with passive scattering systems.
From the end of the century the newly built protontherapy centres feature isocentric 'gantries' to improve the conformity of the treatment, avoiding high doses to healthy tissues by rotating the therapeutic beam around the patient as it is done in all X-ray treatments. The magnetic rigidity of 200 MeV protons is such that a standard magnetic channel capable of doing so has a typical radius of 4-5 m.
In a conventional treatment with X-rays a total dose of 60-70 Gy (lGy= 1 J/kg) is deposited in a tumour target in typically 30 fractions over six weeks to give time for re-oxygenation of hypox ic -and therefore radioresistant -tumour cells and for the transition of tumour cells from radio-resistant cell cycle stages to more sensitive stages. In addition the unavoidably irradiated healthy cells have a chance to repair the radiation damage. Typi cally a proton treatment requires 20 fractions and allows higher doses to the tumour. It has to be remarked that a larger dose is beneficial because even a modest 10% increase of the dose deposited in a tumour gives typically an increased probability of local control of the tumour itself by about 20%. This implies that passing from 60 Gy to 66 Gy, for instance, the control probability increases from 50% to 60%, a not negligible gain. This fact is inde pendent of any clinical trial and is the strongest argument in favour of protontherapy: since proton and X-rays beams produce practically the same biological effects on the irradiated cells, a bet ter spatial distribution immediately translates either in a reduction of the side effects or in an increase of the tumour control proba bility.
Since good review articles on protontherapy have been recently written by E. Pedroni for Europhysics News 
The rationale for Carbon Ion Therapy
Because of smaller scattering in both the lateral and the longitu dinal direction, carbon beams exhibits dose gradients three times steeper than protons. But the main reason for the transition to carbon ions is the increased Relative Biological Effectiveness (RBE) in the last few centimetres of the carbon range. (RBE is defined as the ratio of the photon dose to the particle dose necessary to pro duce the same biological effect, e.g. inactivation of 90% of the irradiated cells.) Dose is a macroscopic parameter that does not describes the microscopic structure of the energy deposition events. It is the spatial distribution of the ionizations around the particle trajec tory -called the 'track structure' -that determines the biological effect. The relevant scale is the diameter of the DNA molecule, the main target of the radiation attack inside the cell nucleus (Fig. 2) .
Because of its importance the DNA molecule is protected by an elaborate repair system that restores with high fidelity the base damages, the single-and most of the double strand breaks. In the tracks of carbon ions the local ionisation density and hence the density of severe DNA lesions becomes so high that repair fails (clustered multiply-damaged sites). Then the reproduction of the tumour cells is hindered and the tumour stops to grow. In many cases the cell internal program for its own destruction (apoptosis) is activated yielding a fast tumour regression. In the 'entrance channel' of a carbon beam, due to the plateau of the energy deposition, the density of severe lesions is lower and DNA damage can be mostly repaired as is in the case of X-rays and pro tons. Thus for carbon ions the increase in RBE is significant mainly over the Spread Out Bragg Peak (SOBP) (Fig. 3) . Since the RBE varies along the SOBP the physical dose has to decrease towards the distal edge in order to achieve a homogeneous biological effect over the simulated tumour volume.
By contrast, for protons only over the last few micrometers is the RBE definitely larger than 1. For this one can state that protons have the same radiobiological effect as X-rays.
Because of the high effectiveness in suppressing the repair, heavy ion beams are most suited for slowly growing, well repairing tumours, which are precisely those tumours that are resistant to pho tons and protons. In these cases, the biological effect at the end of the range is increased 3 -4 times compared to conventional radiations. In summary, carbon ion beams of about 400 MeV/u are indicated for treatment of deep-seated tumours, which are radio-resistant both to X-rays and to protons. These types of tumours are thus the elec tive targets in a carbon ion facility. Proton therapy is well adapted to the cases where a greater tumour dose is needed but where the tumour is not too close to organs at risk because protons have a dose gradient, always 3 times greater than carbon. These arguments are important since a proton therapy facility is about 30% cheaper than a combined proton / carbon ion centre, which requires a total invest ment cost of about 100 M€.
RBE is a complex function of the biological response to the micro scopic structure of the radiation field, i. e. to the radiation quality. Consequently, RBE changes over the treatment area since the radiation quality changes (as indicated by the fragmentation tail of figure 1) and RBE is different for different tissues of different repair capacity. For a quantitative calculation of the RBE effects, a theoretical model, the Local Effect Model (LEM) has been developed at GSI [9] .
In the LEM approach the individual RBE of the tumour to be treat ed (and the healthy tissues to be avoided) is not derived from in vitro data, but is determined from the intrinsic repair capacity as given by the dose response curve of the same tissue to photons. The very suc cessful experience of the more than two hundred patients treated up to now at GSI using this treatment planning fully confirms the basic rationale of these calculations. The IMPT plan of Fig. 4 has been obtained by making use of a code based on LEM. In this case, and in most others, the advantage of an inverse dose profile, with the high dose and high LET at the end of the range, allows reducing the dose to the normal tissues outside the target volume by a factor of 2-3. A further advantage of particle beams, and especially of ions like carbon, is the 'in situ' production of positron emitters such as 10C and UC and 150. Because the stripping of one or two neutrons is a minor perturbation, the residual carbon ions form a maxi mum of ß+ activity close to the Bragg maximum of the stable carbon ions. By monitoring the positron emitting isotopes by a PET camera during and shortly after the beam application (Fig.  5) , the actual stopping points of the beam can be controlled. PET control gives -for the first time in 110 years of radiotherapy -an 'in situ' control of the treated field that also checks all the calcula tions and calibrations of the energy losses used for treatment planning. The online PET technique has been developed by FZR (Dresden) [10] . At Darmstadt 3 year tumour-control rates for chordomas and chondrosarcomas, which were a subsection of the large variety of tumours treated at NIRS, are 100% and 84 % respectively [12] , These values are significantly better than reported for conven tional radiotherapyand are also based on an accelerated fractionation scheme of 20 fractions in 20 days.
Clinical Results and numbers of potential patients
As far as the number of potential patients is concerned, detailed analysis have been made in Germany, Italy, Austria and France by groups of radiotherapists who have applied to the national data specific criteria for each tumour site. The results of these different approaches are very consistent. As an overall summary it can be stated that about 1% of the patients today treated with X rays must be irradiated with protons since the outcomes are definitely better than those of conventional therapy; about 12% of the X-ray patients would profit from a proton treatment but further clinical A Fig. 4: Comparison of treatment plans with 2 fields of carbon ion (IMPT -left panel) and with 9 fields of X-rays (IMRT -right panel) . In both cases the conformity to the target volume is good but for carbon ions the dose to the normal tissues is much smaller. trials are needed to quantify, site by site, the clinical advantages; about 3% of the X ray patients would profit from carbon-ion therapy, but many more dose-escalation studies and clinical trials are needed.
Overall, 15% of the about 20,000 patients out of every 10 mil lion inhabitants treated with conventional radiation would receive a better treatment with hadron beams. If the actual average recruitment rate could be as large as 50%, these figures would require a proton therapy centre (treating 1500 patients a year) for every 10 million people and a carbon ion centre for every 50 mil lion people. This is indeed the conclusion reached by the Italian association for radiotherapy and oncology AIRO [13] .
As far as costs are concerned, it has been said that proton treat ment costs 2-3 times more than conventional treatment [14] . The economy of carbon treatment is different. The possible short ening of the treatment to less than 10 fractions is a great advantage for a very effective use of the costly infrastructures and -if con firmed by the ongoing clinical trials -will reduce the cost of the treatments and may become one of the main reasons behind the rapid diffusion of light ion therapy in the future. At present the German health insurance is negotiating 15,000 to 20,000 € per patient for particle treatment.
European Carbon Ion facilities and enlight
Based on the successes of the pilot project, the Heidelberg Ion Therapy Centre HIT (Fig. 6) The second European centre is being built in Pave: CNAO (the "Centro Nazionale di Adroterapia Oncologica") and has been designed by the TERA Foundation simplifying the PIMMS project. In the PIMMS/TERA design (Fig. 7) the sources are inside the ring together with a single 7 MeV/u injector of the GSI design [ 17] .
In done and the existence of this network, and of its potential suc cessor, guarantees that the future of carbon ion therapy in Europe is on a good track and that the foreseen facilities will be run for the benefit of all European patients.
Finally it should be mentioned that the industry has meanwhile shown its interest in the forthcoming market of heavy-particle therapy. As stated above, five companies are selling proton thera py units. In the heavy-ion market Mitsubishi has designed a "micro HIMAC", a synchrotron for combined proton and carbon therapy and Siemens Medical Solutions has designed a combined proton -carbon facility on the basis of exclusive licenses of the GSI patents and know-how. IBA and ACCEL are studying super conducting cyclotrons for carbon ions and other companies are organizing themselves to enter this promising market. The strong interest of industrial companies in ion therapy indicates the large potential of this novel strategy for combating cancer. ■
